In the setting of allogeneic BMT for the treatment of leukemia or lymphoma, Waller et al. [55] found that the CD34+CD38-- cell content of the graft product was the best predictor for time to reach the recovery parameters of absolute neutrophil count ≥1 × 109/L and platelet count ≥20 × 109/L. Here, CD34 is linked to lymphoma.